In the first nine months of 2018, the Krka Group generated sales in total of €971.9 million, a 5% year-on-year increase, and net profit in the amount of €120.8 million, or 10% more than in the same period last year.
In the first nine months of 2018, the Krka Group generated the strongest sales in a nine-month period since Krka was founded. Sales growth was achieved in all product and service groups and in most markets.
Krka Group Sales by Region
The leading sales region of the Krka Group was Region East Europe that generated €287.6 million revenues, or 29.6% of total sales. In comparison to the same period in 2017, this region recorded the highest absolute sales growth of €16.2 million. With the increased sales compared to the same period last year, the Russian Federation, Krka’s largest individual market, was followed by most other Eastern European and Central Asian markets.
Region Central Europe, which includes the Visegrad Group countries and the Baltic states, was the second largest region in terms of sales, its share accounting for €239.6 million or 24.6% of total Krka Group sales. A 6% year-on-year sales growth was recorded. Poland was leading market in the region, but also other regional markets.
The next largest region in terms of sales was Region West Europe, generating €211 million or 21.7% of total Krka Group sales. Year-on-year sales decreased by 3%. Germany generated the strongest sales, and was followed by markets of Scandinavia, Spain, France, and Italy.
Product sales in Region South-East Europe amounted to €132.3 million, up 14% compared to the same period last year, and accounted for 13.6% of total Krka Group sales. Romania and Croatia, their two key markets, were leading markets of the region, whereas growth rates were the highest in Serbia and Bulgaria.
In Slovenia, Krka recorded €68.6 million or 7.1% of total Krka Group sales. Sales revenues increased by 3%. Krka held an 8.7% market share and remained the leading provider of pharmaceuticals in Slovenia.
Product sales in Region Overseas Markets totalled €32.8 million, a growth rate of 9%, and accounted for 3.4% of total Krka Group sales.
Krka Group Sales by Product and Service Group
Krka Group sales of prescription pharmaceuticals reached €804.3 million, up 5% compared to the same period last year, and accounted for 82.8% of total Krka Group sales.
The ten leading prescription pharmaceuticals in terms of sales included medicines containing perindopril (Prenessa*, Co-Prenessa*, Amlessa*, Co-Amlessa*), valsartan (Valsacor, Valsacombi*, Vamloset*, Co-Vamloset*, Valarox*), losartan (Lorista*, Lorista H*, Tenloris*), atorvastatin (Atoris, Atordapin*), pantoprazole (Nolpaza*), rosuvastatin (Roswera*, Rosudapin*), esomeprazole (Emanera*), enalapril (Enap, Enap H*, Elernap*), clopidogrel (Zyllt*), and tramadol (Doreta*, Tadol*).
Compared to the same period last year, non-prescription product sales were up 5%, and totalled €87.4 million (9% of total Krka Group sales). The sales of animal health products were up 4% reaching €50.4 million, and accounted for 5.2% of total Krka Group sales. Health resort and tourist service sales amounted to €28.3 million, a 4% year-on-year increase (2.9% share of total Krka Group sales).
Research and Development
In the period from January to September 2018, Krka obtained marketing authorisations for sixteen (16) new products in 36 dosage forms and strengths. In the same period, Krka obtained 606 new marketing authorisations in various markets for 103 products.
In the first nine months of the year, the Krka Group allocated €66 million to investments, of that €52 million to the controlling company. Investments primarily aimed to increase and modernise production and research and development capacities.
At the end of September, the Krka Group had 11,226 persons on payroll, or 394 (4%) more than at the end of 2017. Subsidiaries and representative offices abroad employed over 51% of total Krka Group headcount. More than 54% of employees hold at least a university degree. Together with persons employed through agencies, the Krka Group had 12,414 persons on payroll, or 2% more than at the end of 2017.
2018 Krka Group Performance Estimate
Annual sales of products and services are estimated at just over €1.3 billion, which is somewhat above the plan. Sales outside Slovenia are projected to account for 93%. Prescription pharmaceuticals are expected to remain the most important product group, comprising 82% of overall sales. Net profit for 2018 is expected to somewhat exceed the net profit plan of €153 million. Investments in Krka’s own development, manufacturing and infrastructural facilities are expected to total €97 million. At the end of 2018, the Krka Group will employ more than 11,600 regular employees, of that 51% abroad. In 2018, all performance indicators are projected to exceed those achieved in 2017.
2019 Krka Group Plans
According to the 2019 plan, the Krka Group sales are projected at €1.375 million and net profit at €172 million. Investments in increasing and upgrading production capacities and infrastructure are planned at just over €124 million. In 2019, Krka plans to increase the number of employees in Slovenia and abroad by 4%; the total number of regular employees is projected to exceed 12,100.
The 2019 business plan is based on the Krka Group development strategy for the period from 2018 to 2022. It is based on expectations, assessments, projections and other available data at disposal to the Management Board. The Management Board believes that the expectations are reasonable. Should the business conditions in 2019 differ significantly from the projections, operating results may also differ from the plan.